A Study of LY3473329 in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 18, 2020

Primary Completion Date

November 9, 2021

Study Completion Date

November 9, 2021

Conditions

Healthy

Interventions

DRUG

LY3473329

Administered orally.

DRUG

Placebo

Administered orally.

Trial Locations (1)

PRA Health Sciences, Groningen

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT04472676 - A Study of LY3473329 in Healthy Participants | Biotech Hunter | Biotech Hunter